Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ejiao Composite Syrup for diminished ovarian reserve
ChiCTR2300077849Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Oct 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Ejiao Composite Syrup in Diminished Ovarian Reserve (DOR) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Change in serum anti-Müllerian hormone from baseline after 3 menstrual cycles. Started Oct 2023; status: recruiting.
02
Drugs
Ejiao Composite Syrup
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on ChiCTR2300077849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077849.